Lifetime Cannabis Use Not Tied To Dementia In Surprising New Study
A recent study conducted by investigators at Yale University and the University of Oxford in the United Kingdom analyzed cognitive performance among […]
Author: Jason
The Cannabis Industry Forgot Who Built It
Legal cannabis promised legitimacy. Instead, many of the people who carried the culture through prohibition are being priced, regulated, and pushed out […]
Why Does Watching The World Cup Feel Like A Panic Attack? Weed Can Help, If You Don’t Screw It Up.
The World Cup can trigger intense stress responses that closely resemble the body’s reaction to real threats, making anxiety management just as […]
A U.S. Weed Company Finally Cracked The NYSE. It Had To Leave The Recreational Pot Behind.
Trulieve becomes the first U.S. cannabis company to trade on the NYSE on June 10. To get through the door, it carved […]
AI Is Growing Your Weed Now
From robot canopy scanners to algorithmic breeders to AI-powered dispensary counters, artificial intelligence is remaking cannabis at every level. The question nobody […]
The THC Breathalyzer Hype Machine: Why This Technology Still Doesn’t Solve the Problem
The latest version of this story comes from Virginia Commonwealth University, where researcher Emanuele Alves developed a portable, 3D-printed device shaped like […]
From Ditch Weed to Dank: The Lost World of 1977 Cannabis and Why It Still Matters
But there’s more to this image than nostalgia and comedy. What you’re looking at in that High Times spread is a snapshot […]
The WNBA Just Dropped Its Weed Ban. It Banned Psychedelics In The Same Breath.
The league pulled marijuana off its banned list in the new players’ agreement. In the same document, it banned psilocybin, DMT and […]
Medical Cannabis Behind the Wheel: NSW Proposes ‘Three Strikes’ Before Penalties
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So far, so good. But the question that […]
Wall Street Is About to Steal Psychedelics From the People Who Need Them
The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap, zero revenue. MindMed: up to $2 billion, […]